TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03457948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Embolization
Description: Undergo TAE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Undergo yttrium-90 microsphere RE
Study: NCT01876602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feeling states exercise intervention
Description: exercise prescription based on intensity of exercise that feels good.
Study: NCT01467336

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic rotator cuff repair
Description: Arthroscopic rotator cuff repair for all groups

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic rotator cuff repair
Description: Arthroscopic rotator cuff repair for all groups

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic rotator cuff repair
Description: Arthroscopic rotator cuff repair for all groups
Study: NCT01567033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAT Curriculum + Health Information
Description: Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
Study: NCT02157428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT01881789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally
Study: NCT01881789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Extended release (ER) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.
Study: NCT03801382

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Paper-Pencil Tests
Description: The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Paper-Pencil Tests
Description: The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Paper-Pencil Tests
Description: The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
Study: NCT01881789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
Study: NCT00834821

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Focused Training (PFT)
Description: PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS) Program
Description: CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
Study: NCT02379052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02332473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ypeginterferon alfa-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor
Study: NCT01686113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEFA
Study: NCT01272726

Intervention type: BEHAVIORAL
Intervention: Education
Description: Education on the genetics of ADHD and treatment options for ADHD
Study: NCT00000396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient self-care education
Study: NCT01686113

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Study: NCT01497834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (Daclatasvir)
Description: Tablets, Oral, 60mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 (Asunaprevir)
Description: Capsules, Oral, 100mg, Twice daily, 24 weeks
Study: NCT00499525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: given orallly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: given orally
Study: NCT02328742

Intervention type: BIOLOGICAL
Intervention: Hysteroscopy + endometrial biopsy
Description: The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study.

Intervention type: BIOLOGICAL
Intervention: Hysteroscopy + endometrial biopsy
Description: The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study.

Intervention type: BIOLOGICAL
Intervention: Hysteroscopy + endometrial biopsy
Description: The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study.

Intervention type: OTHER
Intervention: Telephone call
Description: Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study.
Study: NCT03571841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Session
Description: The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
Study: NCT02328742

Intervention type: OTHER
Intervention: Telephone call
Description: Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study.

Intervention type: OTHER
Intervention: Telephone call
Description: Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study.

Intervention type: BIOLOGICAL
Intervention: Resection + endometrial biopsy
Description: If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study.

Intervention type: BIOLOGICAL
Intervention: Resection + endometrial biopsy
Description: If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study.

Intervention type: BIOLOGICAL
Intervention: Follow-up hysteroscopy + endometrial biopsy
Description: For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study.

Intervention type: BIOLOGICAL
Intervention: Follow-up hysteroscopy + endometrial biopsy
Description: For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study.
Study: NCT02909738

Intervention type: OTHER
Intervention: Volunteer to pedal a bicycle
Study: NCT03571841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Booster
Description: One month following the group session, women will receive a telephone booster session (\<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
Study: NCT01861054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: 1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
Study: NCT02264899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: in Memento-VASCOD
Description: * Pulse wave velocity assessment~* Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~* Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~* Neuropsychological testing and behaviorial and mood scales~* Urinary albumin excretion measurement
Study: NCT04669470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bariatric endoscopy, mainly intragastric baloons, plication of stomach too
Description: bariatric endoscopy, mainly intragastric baloons, plication of stomach too

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bariatric endoscopy, mainly intragastric baloons, plication of stomach too
Description: bariatric endoscopy, mainly intragastric baloons, plication of stomach too
Study: NCT02435836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study: NCT01011036

Intervention type: DRUG
Group type: OTHER
Intervention: clobazam
Description: test substance

Intervention type: DRUG
Group type: OTHER
Intervention: clobazam
Description: test substance

Intervention type: DRUG
Group type: OTHER
Intervention: clobazam
Description: test substance

Intervention type: DRUG
Group type: OTHER
Intervention: clonazepam
Description: positive control

Intervention type: DRUG
Group type: OTHER
Intervention: clonazepam
Description: positive control

Intervention type: DRUG
Group type: OTHER
Intervention: clonazepam
Description: positive control

Intervention type: DRUG
Group type: OTHER
Intervention: tolterodine
Description: active placebo

Intervention type: DRUG
Group type: OTHER
Intervention: tolterodine
Description: active placebo

Intervention type: DRUG
Group type: OTHER
Intervention: tolterodine
Description: active placebo
Study: NCT03784521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-line filtration
Description: In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients are treated with standard intravenous solutions and vascular access management
Study: NCT03438396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
Study: NCT02899832

Intervention type: DEVICE
Intervention: NIRS
Description: Near Infra Red Spectroscopy
Study: NCT04393766

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline(crystalloids)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: normal saline(crystalloids)
Study: NCT01876602

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: feeling states exercise intervention
Description: exercise prescription based on intensity of exercise that feels good.
Study: NCT01376089

Intervention type: DRUG
Group type: OTHER
Intervention: Iodixanol
Description: Iodixanol 320 mg I/mL as a single iv. administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol
Description: Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
Study: NCT01888848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried Blueberry
Description: 12g freeze-dried blueberry (powder), twice daily with water, for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blueberry Placebo
Description: 12g blue, blueberry-flavored powder, twice daily with water, for 90 days
Study: NCT01507038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14617
Description: 1mg once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14617
Description: 1.6mg once weekly
Study: NCT02318771

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Given IV
Study: NCT00569608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Discharge
Description: Application of an early discharge protocol from the neonatal intensive care unit.
Study: NCT02893137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: For further information see www.optune.com

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniectomy
Description: A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
Study: NCT03525743

Intervention type: DEVICE
Intervention: NICOM (Non invasive cardiac output monitor)
Description: Non invasive hemodynamic device utilizing bioreactance
Study: NCT00448136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU
Description: 400mg/m2/day iv on days 1-5 every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptozotocin
Description: 500mg/m2/day iv on days 1-5 every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: 1000mg/m2 po bid on days 1-14 every 3 weeks
Study: NCT01744093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 100 mg twice daily (BID orally) x 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: 100 mg twice daily (BID orally) x 24 weeks
Study: NCT01403064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: IV Infusion
Study: NCT03245957

Intervention type: OTHER
Intervention: Ischemic stroke
Description: Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan

Intervention type: OTHER
Intervention: Haemorrhagic stroke
Description: Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
Study: NCT02674061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle
Study: NCT00732433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: digital mammography
Description: Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
Study: NCT01507038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14617
Description: 2mg once biweekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once weekly
Study: NCT02190097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Description: see procedures section for more details

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Diabetes Association diet
Description: see procedures section
Study: NCT01925469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzocaine
Study: NCT02727361

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET (Positron Emission Tomography) imaging
Description: Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
Study: NCT01925469

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: A saline spray will be used in the placebo group
Study: NCT04080336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
Study: NCT03305146

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Molecular biology analysis of pancreatic intra-cyst fluid
Description: The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( \<50ng) DNA.
Study: NCT02594631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESWL
Description: Patients in this arm will receive ESWL for treatment of acute calcular urinary retention